• Received 10 device purchase orders in Q2 FY25, a 150% increase over Q2 FY24
• Signed formal agreement with Stryker to expand commercial arrangements in Australia and New Zealand
• Cash at end of Q2 was A$8.8m, with expected A$6.0m in receipts from customers in H2 FY25

CurveBeam Ai Ltd received purchase orders (POs) for ten (10) devices in Q2 FY25, representing around A$5m in future sales for the quarter. This is a 150% increase compared to the prior corresponding period of four (4) devices in Q2 FY24. Eight (8) of the orders were for the HiRise™ device, which was a record quarter for purchase orders. Five (5) of the HiRise orders were through Stryker. In total, the company received 13 POs for the six-month period to 31 December 2024, up almost 100% from the prior corresponding period. The company also made progress on the validation of its Enhanced HiRise™ platform for robotic surgical systems, with the first 5 of 10 matched datasets currently being processed. CurveBeam Ai completed the Q-Sub meeting with the FDA on its proposed new BMD (MDCT) regulatory strategy, which will result in a 6-month delay for filing with the FDA. The company's cash position at the end of Q2 was A$8.8m, resulting in a calculation of 3.2 quarters of funding. CurveBeam Ai expects to receive a further A$6.0m in receipts from customers over H2 FY25 from existing POs as devices are shipped and installed.

The company expects to receive a further A$6.0m in receipts from customers over H2 FY25 from existing purchase orders as devices are shipped and installed.

The company remains confident in its pipeline over the remainder of the financial year and is focusing on opportunities not reliant on robotic datasets for Q3 closes. The company is targeting a FY25 Q3 timeline for completing the validation of the Enhanced HiRise™ platform for hip and knee robotic surgical systems.